翻译成英文维持治疗方案为：呋喹替尼 5 mgqd po连续用药三周停药一周每四周为一个治疗周期。连续服用半年或半年内直至肿瘤复发、转移或不可耐受药物毒副反应。达到NED后2年内每6月复查一次胸腹盆部CT增强或胸部CT+腹盆部MRI增强；每年复查一次肠镜；每3个月复查一次CEA、CA19-9和腹盆部彩超异常者随时复查影像学检查及肠镜必要时行PETCT检查。试验过程中患者发生的药物毒副反应按照 NCI

The maintenance treatment plan is as follows: Fruquintinib 5 mg, once daily, orally, with three weeks of continuous treatment followed by one week of drug discontinuation. Each treatment cycle lasts four weeks. The treatment will be continued for six months, or until tumor recurrence, metastasis, or intolerable drug toxicities occur within six months. After achieving no evidence of disease (NED), a chest, abdomen, and pelvic CT scan with contrast or a chest CT scan with abdominal and pelvic MRI scan will be performed every 6 months within 2 years. Colonoscopy will be performed annually. CEA, CA19-9, and abdominal and pelvic ultrasound will be performed every 3 months. If abnormalities are found, further imaging studies and colonoscopy will be conducted, and if necessary, a PET/CT scan will be performed. Adverse drug reactions that occur during the trial will be graded according to the NCI CTCAE version 5.0 and dose adjustments will be made according to the corresponding rules.